An observational study to evaluate the quality of life of patients treated with phytotherapy or alpha-blockers for benign prostatic hyperplasia (PERQOL).

A 6-months prospective, observational study to evaluate the quality of life of patients treated with phytotherapy or alpha-blockers for benign prostatic hyperplasia.

Hide study title
Status
Status :
Active
Type of study
RWE
Min. Age
40
Years old
Max. Age
-
Gender
Male

Brief summary

Benign prostatic hyperplasia (BPH) is a very common disease of aging men (over half of the population concerned after 50 years). In some cases, BPH induces urinary discomfort and disturbances called lower urinary tract symptoms (LUTS). BPH may also be associated to sexual dysfunction.

BPH can have a marked effect on patient’s quality of life (QoL), particularly when symptoms are moderate or severe.

In this context, the purpose of PERQOL, a prospective and observational study, is to assess the impact of LUTS/BPH treatment on patients’ QoL and sexual function using dedicated questionnaires.

Therapeutic area :
Urology
Disease :
Benign prostatic hyperplasia
Study medication :
Phytotherapy and alpha-blockers
Phase : RWE
Start Date :
June 2022
End Date / Planned study Completion Date :
February 2024
Study ID : NIS13199
Countries :
France
Spain

Contact Us

Need more information, click on the button to have access to the contact form.

Contact Us

Access to Lay Protocol Synopsis

Un résumé du protocole rédigé en termes simples et décrivant les objectifs de l’étude vous est proposé  

Send by email